ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,303.27
      0.12%
      US Tech 100
      18,062.00
      -0.10%
      Dow Jones
      40,003.59
      0.34%
      Brent Oil
      83.76
      0.00%
      Bitcoin
      67,003.20
      0.09%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. BeyondSpring Inc (BYSI)

      7. BeyondSpring Inc (BYSI) News

      BYSI

      BeyondSpring (BYSI)

      BeyondSpring Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:BYSI
      DateTimeSourceHeadlineSymbolCompany
      05/16/20248:00AMGlobeNewswire Inc.BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsNASDAQ:BYSIBeyondSpring Inc
      05/03/20247:00AMGlobeNewswire Inc.BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsNASDAQ:BYSIBeyondSpring Inc
      04/29/20245:30PMGlobeNewswire Inc.BeyondSpring Files 2023 Annual Report on Form 20-FNASDAQ:BYSIBeyondSpring Inc
      04/29/20245:30PMGlobeNewswire Inc.BeyondSpring Provides Business Update and Reports Year End 2023 Financial ResultsNASDAQ:BYSIBeyondSpring Inc
      03/25/20247:00AMGlobeNewswire Inc.BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung CancerNASDAQ:BYSIBeyondSpring Inc
      02/26/20248:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
      02/26/20248:00AMGlobeNewswire Inc.BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing RequirementsNASDAQ:BYSIBeyondSpring Inc
      02/14/20244:30PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BYSIBeyondSpring Inc
      02/02/20244:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
      01/16/20244:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
      01/10/20243:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
      01/10/20243:00PMGlobeNewswire Inc.BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-KNASDAQ:BYSIBeyondSpring Inc
      12/18/20234:31PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
      12/18/20234:30PMGlobeNewswire Inc.BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsNASDAQ:BYSIBeyondSpring Inc
      11/07/20237:00AMGlobeNewswire Inc.BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 InhibitorsNASDAQ:BYSIBeyondSpring Inc
      10/31/20238:00AMGlobeNewswire Inc.BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere ModelsNASDAQ:BYSIBeyondSpring Inc
      10/30/20238:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
      10/30/20238:00AMGlobeNewswire Inc.BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:BYSIBeyondSpring Inc
      10/26/20238:30AMGlobeNewswire Inc.SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” SymposiumNASDAQ:BYSIBeyondSpring Inc
      10/23/20237:45AMGlobeNewswire Inc.SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of DirectorsNASDAQ:BYSIBeyondSpring Inc
      10/04/20234:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
      10/04/20233:55PMGlobeNewswire Inc.BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsNASDAQ:BYSIBeyondSpring Inc
      09/27/202310:00AMGlobeNewswire Inc.BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual MeetingNASDAQ:BYSIBeyondSpring Inc
      09/20/20235:20PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
      09/07/20238:00AMGlobeNewswire Inc.BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare ConferenceNASDAQ:BYSIBeyondSpring Inc
      07/14/20234:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
      06/20/20238:00AMGlobeNewswire Inc.SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of DirectorsNASDAQ:BYSIBeyondSpring Inc
      06/07/20238:00AMGlobeNewswire Inc.BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCTNASDAQ:BYSIBeyondSpring Inc
      05/18/20238:30AMGlobeNewswire Inc.BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual MeetingNASDAQ:BYSIBeyondSpring Inc
      05/12/20234:31PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BYSIBeyondSpring Inc
       Showing the most relevant articles for your search:NASDAQ:BYSI